Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edoxaban vs Warfarin after thoracoscopic ablation for AF
NCT04121767Completed
- Sponsor
- Samsung Medical Center
- Start
- Dec 2017
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of edoxaban in Atrial fibrillation (AFib), sponsored by Samsung Medical Center. Primary endpoint: Postoperative stroke at 6 months. Started Dec 2017; status: completed.
02
Drugs
edoxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT04121767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04121767.